EU COVID-19 Therapeutics Strategy
In combination with an increasing vaccination rate, better access to therapeutics means fewer hospitalisations, speedier recovery for COVID-19 patients and ultimately more lives saved. The EU strategy on COVID-19 therapeutics aims to support the development and increase the availability of much-needed COVID-19 therapeutics, notably through quicker authorisation. It covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment.
